PMID- 21399868
OWN - NLM
STAT- MEDLINE
DCOM- 20110803
LR  - 20211020
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 38
IP  - 5
DP  - 2011 May
TI  - p53, HER2 and tumor cell apoptosis correlate with clinical outcome after 
      neoadjuvant bevacizumab plus chemotherapy in breast cancer.
PG  - 1445-52
LID - 10.3892/ijo.2011.966 [doi]
AB  - Bevacizumab, an antibody to vascular endothelial growth factor (VEGF), has been 
      incorporated into chemotherapy regimens in the treatment of several cancer types 
      including breast cancer. The aim of this study was to identify tumor and 
      angiogenic factors that potentially associate with outcome. In a pilot trial, 21 
      patients with inflammatory breast cancer and locally advanced breast cancer 
      received bevacizumab plus doxorubicin-docetaxel chemotherapy before surgery. 
      Baseline p53, HER2, tumor apoptosis, Ki67, estrogen receptor (ER), VEGF-A, serum 
      VEGF (sVEGF), VEGFR2-Y951 and microvessel density (MVD) were prospectively 
      designed and determined by immunohistochemistry and enzyme-linked immunosorbent 
      assay. Hazard ratios (HR) and 95% confidence intervals for survival and 
      progression-free survival (PFS) were estimated using Cox proportional hazards 
      analyses. With a median follow-up of 65.9 months, patients with low apoptosis or 
      p53-negative tumors had significantly longer survival than those with high 
      apoptosis or p53-positive tumors (median 61.5 vs. 20.2 months; HR 0.22; p=0.011 
      for apoptosis and median 59.6 vs. 24.2 months; HR 0.27; p=0.016 for p53). Low 
      Ki67 versus high Ki67 exhibited a trend towards association with survival (median 
      57.1 vs. 17.3 months, HR 0.34, p=0.07). Patients with HER2-negative tumors had 
      significantly longer PFS than those with HER2-positive tumors (median 31.2 vs. 
      9.4 months; HR 0.23; p=0.03). ER, VEGF-A, sVEGF, VEGFR2-Y951 and MVD were not 
      significantly associated with outcome. Our data suggest that baseline p53, 
      apoptosis and HER2 are each significantly associated with outcome in patients who 
      received bevacizumab plus chemotherapy.
FAU - Yang, Sherry X
AU  - Yang SX
AD  - National Clinical Target Validation Laboratory, Division of Cancer Treatment and 
      Diagnosis, National Cancer Institute, National Institutes of Health, Bldg. 37/Rm 
      1048, Bethesda, MD 20892, USA. xy32m@nih.gov
FAU - Steinberg, Seth M
AU  - Steinberg SM
FAU - Nguyen, Dat
AU  - Nguyen D
FAU - Swain, Sandra M
AU  - Swain SM
LA  - eng
GR  - Z01 BC010560/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20110309
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Apoptosis/*drug effects
MH  - Bevacizumab
MH  - Breast Neoplasms/chemistry/*drug therapy/mortality/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Proportional Hazards Models
MH  - Receptor, ErbB-2/*analysis
MH  - Tumor Suppressor Protein p53/*analysis
PMC - PMC7316373
MID - NIHMS1597155
EDAT- 2011/03/15 06:00
MHDA- 2011/08/04 06:00
PMCR- 2020/06/25
CRDT- 2011/03/15 06:00
PHST- 2010/11/04 00:00 [received]
PHST- 2010/12/20 00:00 [accepted]
PHST- 2011/03/15 06:00 [entrez]
PHST- 2011/03/15 06:00 [pubmed]
PHST- 2011/08/04 06:00 [medline]
PHST- 2020/06/25 00:00 [pmc-release]
AID - 10.3892/ijo.2011.966 [doi]
PST - ppublish
SO  - Int J Oncol. 2011 May;38(5):1445-52. doi: 10.3892/ijo.2011.966. Epub 2011 Mar 9.